HF
KAPA

HRT Financial’s Kairos Pharma KAPA Stock Holding History

HRT Financial’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
21,575
+256
+1% +$171 ﹤0.01% 3622
2025
Q4 		$15K Buy
+21,319
New +$20K ﹤0.01% 3020
2025
Q3 		– Sell
-13,239
Closed -$9K – 3858
2025
Q2 		$9K Buy
+13,239
New +$9.63K ﹤0.01% 2460
2024
Q4 		– Sell
-12,609
Closed -$19K – 3426
2024
Q3 		$19K Buy
+12,609
New +$25.8K ﹤0.01% 2194

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HRT Financial's KAPA Position: Q1 2026 in Review

HRT Financial increased its Kairos Pharma (KAPA) stake by 1.2% in Q1 2026, buying an estimated $171 and bringing the position to 21,575 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3622.

HRT Financial first reported a position in KAPA in Q3 2024 and has held it in 4 quarters since. The position peaked at $19K in Q3 2024. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • HRT Financial held 21,575 shares of Kairos Pharma worth $12K as of Q1 2026.
  • HRT Financial bought 256 Kairos Pharma shares in Q1 2026, an estimated $171.
  • Kairos Pharma made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3622 holding.
  • HRT Financial first reported a position in Kairos Pharma in Q3 2024 and has held it in 4 quarters since.
  • HRT Financial's Kairos Pharma position peaked at $19K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.